In addition, BCR::ABL1‐independent pathways and molecules or niche‐related factors may trigger growth and survival of leukemic stem cells (LSC) in CML and thereby contribute to drug resistance.26, 27, 28. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.